SEARCH:   Advanced

Blood, 1 January 2007, Vol. 109, No. 1, pp. 244-252. Prepublished online as a Blood First Edition Paper on August 10, 2006; DOI 10.1182/blood-2006-05-021931. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2006-05-021931v1 109/1/244    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kreijveld, E. Articles by Joosten, I. Search for Related Content PubMed PubMed Citation Articles by Kreijveld, E. Articles by Joosten, I. Related Collections Signal Transduction Immunotherapy Immunobiology Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  IMMUNOBIOLOGY The immunosuppressive drug FK778 induces regulatory activity in stimulated human CD4+CD25– T cells Ellen Kreijveld1, Hans J. P. M. Koenen1, Luuk B. Hilbrands2, Hans J. P. van Hooff3, and Irma Joosten1, 1 Department of Blood Transfusion and Transplantation Immunology, Radboud University Nijmegen Medical Centre, The Netherlands; 2 Department of Nephrology, Radboud University Nijmegen Medical Centre, The Netherlands; and 3 Department of Internal Medicine, University Hospital Maastricht, The Netherlands The induction of transplantation tolerance involves a T-cell–mediated process of immune regulation. In clinical transplantation, the use of immunosuppressive drugs that promote or facilitate this process would be highly desirable. Here, we investigated the tolerance-promoting potential of the immunosuppressive drug FK778, currently under development for clinical therapy. Using a human allogeneic in vitro model we showed that, upon T-cell receptor (TCR) triggering, FK778 induced a regulatory phenotype in CD4+CD25– T cells. Purified CD4+CD25– T cells primed in the presence of FK778 showed hyporesponsiveness upon restimulation with alloantigen in the absence of the drug. This anergic state was reversible by exogenous interleukin-2 (IL-2) and was induced independent of naturally occurring CD4+CD25+ regulatory T cells. Pyrimidine restriction was a crucial requirement for the de novo induction of regulatory activity by FK778. The FK778-induced anergic cells showed suppressor activity in a cell-cell contact–dependent manner; were CD25high, CD45RO+, CD27–, and CD62L–; and expressed cytotoxic T-lymphocyte–associated antigen-4 (CTLA-4), glucocorticoid-induced tumor necrosis factor receptor (GITR), and FoxP3. The cells revealed delayed p27kip1 degradation and enhanced phosphorylation of STAT3. In conclusion, the new drug FK778 shows tolerizing potential through the induction of a regulatory T-cell subset in CD4+CD25– T cells. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: X. Feng, S. Kajigaya, E. E. Solomou, K. Keyvanfar, X. Xu, N. Raghavachari, P. J. Munson, T. M. Herndon, J. Chen, and N. S. Young Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro Blood, April 1, 2008; 111(7): 3675 - 3683. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020